Transpara
AI solution for breast cancer detection and diagnosis
Transpara assists radiologists in their interpretation of a mammography exam. Transpara provides a probability of the presence of breast cancer based on automatically detected and AI-scored lesions.
Automatic lesion detection: soft tissue lesions and microcalcifications
Segmentation and contouring of suspicious regions.
Evaluation of the level of malignancy of each lesion detected.
Definition of a regional score for each microcalcification and suspicious tissue lesion.
Analysis of the overall probability that cancer is present in a mammogram.
Categorization of the examination based on an overall score.
- breast cancer
- microcalcifications
- tomosynthesis
- mammography
- soft tissue injury
- 3D
- lesion
Save time, reassure your diagnosis and streamline your workflow with Incepto
Testimonial
When I see a score of 1 or 2, even in dense breasts, I become very calm. Obviously, I analyze the mammogram very carefully, but more calmly and quickly than before, which leaves me more time to focus on the less favorable results. On the other hand, when the scores are 8, 9 and 10, I trust the abnormalities indicated by Transpara and I am even more attentive to my analysis.
Dr Marc Abehsera,
Senologist and radiologist
Paris American Hospital
Publications
- Schaffter, T. et al. Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. JAMA Netw Open 3, e200265 (2020).
- Sasaki, M. et al. Artificial intelligence for breast cancer detection in mammography: experience of use of the ScreenPoint Medical Transpara system in 310 Japanese women. Breast Cancer 27, 642–651 (2020).
- Lång, K. et al. Identifying normal mammograms in a large screening population using artificial intelligence. Eur Radiol (2020) doi:10.1007/s00330-020-07165-1.
- Rodriguez-Ruiz, A. et al. Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study. Eur Radiol 29, 4825–4832 (2019).
- Rodriguez-Ruiz, A. et al. Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists. 7 (2019).
- Le, E. P. V., Wang, Y., Huang, Y., Hickman, S. & Gilbert, F. J. Artificial intelligence in breast imaging. Clinical Radiology 74, 357–366 (2019).
- Bahl, M. Detecting Breast Cancers with Mammography: Radiology 2 (2019) doi:https://doi.org/10.1148/radiol.2018182404.
- Rodríguez-Ruiz, A. et al. Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System. Radiology 181371 (2018) doi:10.1148/radiol.2018181371.
- Hupse, R. et al. Computer-aided Detection of Masses at Mammography: Interactive Decision Support versus Prompts. Radiology 266, 123–129 (2013).
ScreenPoint Medical is a Dutch company founded in 2014 by Professors Nico Karssemeijer and Mike Brady. Pioneers in their field, they assembled a team of experts in breast imaging and artificial intelligence to develop a decision support algorithm. The team’s ultimate goal is to facilitate early detection of breast cancer, improving survival rates and enabling earlier treatment with less invasive methods.
The Transpara medical device is a regulated health product bearing the CE mark, Class IIb. Notified Body: DEKRA Certification B.V. n°0344. Manufacturer: ScreenPoint Medical B.V.
Transpara is a diagnostic aid and should not be used on its own to recommend medical treatment for diagnostic purposes. Please read the user manual carefully. Please contact contact@incepto-medical.com for further information. Last update : 25/03/2024